Starling Oncology Inc(TOI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.38 | Insider Own | 36.51% | Shs Outstand | 100.0M | Perf Week | -1.16% |
| Market Cap | 0.51B | Forward P/E | - | EPS next Y | 81.88% | Insider Trans | 1.77% | Shs Float | 63.5M | Perf Month | -2.84% |
| Enterprise Value | 0.59B | PEG | - | EPS next Q | -0.06 | Inst Own | 35.31% | Short Float | 11.46% | Perf Quarter | 26.67% |
| Income | -0.04B | P/S | 0.94 | EPS this Y | 74.44% | Inst Trans | 0.77% | Short Ratio | 3.79 | Perf Half Y | 89.3% |
| Sales | 0.55B | P/B | - | EPS next 5Y | - | ROA | -21.84% | Short Interest | 7.27M | Perf YTD | 44.1% |
| Book/sh | -0.16 | P/C | 16.94 | EPS past 3/5Y | -37.23% -17.58% | ROE | -3407.86% | 52W High | -23.09% ($6.67) | Perf Year | 37.53% |
| Cash/sh | 0.3 | P/FCF | - | Sales past 3/5Y | 25.81% 21.8% | ROIC | -44.7% | 52W Low | 121.12% ($2.32) | Perf 3Y | 440% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 46.1% | Gross Margin | 13.88% | Volatility(W/M) | 7.53% 7.71% | Perf 5Y | -48.18% |
| Dividend TTM | - | EV/Sales | 1.08 | Sales Y/Y TTM | 35.37% | Oper. Margin | -5.99% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.17 | EPS Q/Q | 90.12% | Profit Margin | -6.65% | RSI (14) | 48.47 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.47 | Sales Q/Q | 41.22% | SMA20 | -5.2% ($5.41) | Beta | 0.41 | Target Price | $8.4 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -0.62% ($5.16) | Rel Volume | 0.66 | Prev Close | $4.86 |
| Employees | 641 | LT Debt/Eq | - | EPS/Sales Surpr. | 77.14% 3.76% | SMA200 | 32.99% ($3.86) | Avg Volume(3M) | 1.92M | Price | $5.13 |
| IPO | 2020/6/4 | Option/Short | Yes/Yes | Trades | 10294 | Volume | 1,262,010 | Change | 5.56% |
🩺 Oncology Institute TOI is a US-based community-focused, value-based oncology care medical group. Through a network of more than 60 clinic locations, it delivers integrated cancer care—including anti-cancer treatment, drug dispensing, and clinical trials—in a community setting, with a focus on expanding access to evidence-based treatment for a large number of patients.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded less than usual. That is 66% of its average volume.
TOI has a sound balance sheet but weak earning power
Of every $100 in sales, $5.99 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +74.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $94. Peers typically go for $89.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -48.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 35.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #34 of 49 in the industry
Based on market cap of $513M.
STLN#32 Starling Oncology Inc $663M PER - 
GMRS#33 GMR Solutions Inc $617M PER - TOI#34 Starling Oncology Inc $513M PER - 
SRTA#34 Strata Critical Medical Inc $420M PER - 
AUNA#35 Auna SA $355M PER 87.9 
FAQ
What kind of company is TOI?
TOI belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of TOI?
The market cap of TOI is approximately $513M, ranking 3,184 within its sector.
What is the 52-week high and low for TOI?
TOI has recorded a 52-week high of $6.67 and a low of $2.32.
